401P Vibostolimab coformulated with pembrolizumab (vibo/pembro) + chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study
Hsu, C-H., Dziadziuszko, R., Abreo, D.A. Gomez, Aksoy, S., Martín, M. Gil, Roderburg, C., Yen, C.J., Arican, A., Cassier, P., Im, S-A., Kim, S-B., Kudo, T., Ochsenreither, S., Sendur, M.A.N., Yonemori, K., Rojas, C.I., Liu, Q., Keenan, T., Healy, J., Kwiatkowski, M.
Published in Annals of oncology (01.06.2024)
Published in Annals of oncology (01.06.2024)
Get full text
Journal Article